The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of
repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of
proliferative vitreoretinopathy.